TR
Trinity Biotech plc
TRIB · NASDAQ
$7.35 +2.23% (+$0.16)
1M -28.85%
Market Cap $7.44M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$9.59
30.5% upside
Current Price
$7.35
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TRIB is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.17x
EV/EBITDA N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 11.10%
FCF growth N/A
Book val. growth N/A
Profitability
14 /100
Weak Net margin 85.32%
Op. margin 25.66%
FCF margin 14.46%
Quality
7 /100
Poor ROA 35.59%
Asset turnover 0.42x
ROIC 15.14%
Debt
0 /100
High Int. coverage -0.53x
Current ratio 0.25x
Net debt/EBITDA N/A
Stability
61 /100
Moderate Rev. volatility 18.49%
EPS volatility 31.66%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TRIB
Online
Sector
Healthcare
Industry
Medical - Specialties
CEO
John Gillard
Employees
287
Headquarters
Bray
Upcoming events
10 DEC
Earnings
Upcoming earnings report